In murine models of DCM, treatment with exenatide was found to impact glucose homeostasis through improved glucose tolerance, increased myocardial GLUT4 expression and 2-deoxyglucose uptake, and greater cardiac contractility (50). This evidence concerns the gene SLC2A4 and familial dilated cardiomyopathy.